AstraZeneca says ARISE phase III trial unsuccessful, co evaluating data |
|
|
|
Published
:
Mon, 19 Mar 2007 11:56 |
LONDON (AFX) - AstraZeneca PLC said the first results from a phase III clinical outcomes trial which studied AGI-1067, an investigational anti-atherosclerotic agent, show the trial did not meet its primary endpoint, and it will decide whether to continue collaborating with AtheroGenics Inc on the agent after a full analysis.newsdesk@afxnews.comlamCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|